A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms HAWK
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Aug 2017 This trial has been completed in Germany (End date: 2017-08-02).
    • 28 Apr 2017 Planned End Date changed from 1 Aug 2017 to 30 Mar 2018.
    • 04 Jan 2017 This trial was suspended in Spain, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top